Disclaimer:

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7975 - MYLAN / MEDA

SECTION 1.2

Description of the concentration

1. This notification relates to the proposed concentration pursuant to Article 4 of Council Regulation 139/2004 by which Mylan will acquire sole control over Meda.

2. The business activities of the undertakings concerned are:

   - Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

   - Meda manufactures, markets and distributes both generic and specialty pharmaceuticals, in addition to OTC and consumer healthcare products.